Baxter Aktiengesellschaft

Takeda Pharmaceutical Company Limited

Baxalta Gmbh

H Peter Matthiessen

Peter Turecek

Hans-Peter Schwarz

Yendra Linnau

Ernst Hetzl

Erwin Mattes

Wolfgang Sch&ouml;nhofer

Silvia Neppl

Peter L Turecek

A native, chromatographically purified &#x3b1;1-AT preparation having a purity of at least 0.7 PU/mg protein and a relative plasma &#x3b1;1-AT activity of at least 120% is disclosed. The ratio of active to inactive &#x3b1;1-AT is higher than in plasma. Furthermore, a method of producing this preparation is disclosed, as well as the use of a carrier material, e.g. an inorganic carrier material such as hydroxylapatite for separating active &#x3b1;1-AT from inactive &#x3b1;1-AT.

Alpha 1-antitrypsin preparation as well as a method for producing the same

A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex on an anion exchanger material. Second, the method involves separating the AT III from the adsorbed AT III/heparin complex or an AT III/heparinoid complex by elution with a buffer having a pH ranging from 8.5 to 10.5 and a conductivity between 10 and 60 mS.

Method for purification of antithrombin III using an anion exchanger

Growing community of inventors

Vienna, Austria

H Peter Matthiessen